PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for AREG

Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
No VIP available No Clinical Annotations available VA
rs10034692 15630454A>G, 37578A>G, 75419787A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs11725706 15538775G>A, 75328108G>A
G > A
Not Available
No VIP available CA VA
rs11942466 15632745C>A, 39869C>A, 75422078C>A
C > A
Not Available
No VIP available CA VA
rs13104811 13103G>A, 15605979G>A, 75395312G>A
G > A
Not Available
No VIP available CA VA
rs1353295 15539789G>A, 75329122G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs1615111 15521759G>A, 75311092G>A
A > G
No VIP available No Clinical Annotations available VA
rs2132065 15535971A>T, 75325304A>T
A > T
Not Available
No VIP available No Clinical Annotations available VA
rs3913032 15547526A>C, 75336859A>C
A > C
Not Available
No VIP available No Clinical Annotations available VA
rs6447003 15597581G>C, 4705G>C, 75386914G>C
G > C
Not Available
No VIP available CA VA
rs9996584 15632628A>G, 39752A>G, 75421961A>G
A > G
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142


Alternate Names:  AREGB; SDGF
Alternate Symbols:  None
PharmGKB Accession Id: PA24933


Cytogenetic Location: chr4 : q13.3 - q13.3
GP mRNA Boundary: chr4 : 75310853 - 75320726
GP Gene Boundary: chr4 : 75300853 - 75323726
Strand: plus


UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

No related genes are available

Curated Information ?

Curated Information ?

Publications related to AREG: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenetics and genomics. 2014. Wakatsuki Takeru, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. The pharmacogenomics journal. 2013. Sebio A, et al. PubMed


Entrez Gene:
UCSC Genome Browser:
RefSeq RNA:
RefSeq Protein:
Comparative Toxicogenomics Database:
HumanCyc Gene:

Common Searches